Quick Answer
ATOSSA THERAPEUTICS, INC. reported Cash and Equivalents of $41.30 million for fiscal year 2025.
ATOSSA THERAPEUTICS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $41.30M | -41.9% |
| 2024 | $71.08M | -19.6% |
| 2023 | $88.46M | -20.2% |
| 2022 | $110.89M | -18.7% |
| 2021 | $136.38M | +244.8% |
| 2020 | $39.55M | +214.4% |
| 2019 | $12.58M | +21.2% |
| 2018 | $10.38M | +43.8% |
| 2017 | $7.22M | +138.4% |
| 2016 | $3.03M | -18.5% |
| 2015 | $3.72M | -56.3% |
| 2014 | $8.50M | +34.0% |
| 2013 | $6.34M | +267.6% |
| 2012 | $1.73M | -9.7% |
| 2011 | $1.91M | +18536.7% |
| 2010 | $10.3K | — |
| 2009 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $51.84M | -30.7% | -10.4% |
| June 30, 2025 | $57.86M | -27.2% | -11.1% |
| March 31, 2025 | $65.12M | -22.4% | -8.4% |
| December 31, 2024 | $71.08M | -19.6% | -4.9% |
| September 30, 2024 | $74.77M | -20.5% | -6.0% |
| June 30, 2024 | $79.53M | -20.0% | -5.3% |
| March 31, 2024 | $83.96M | -19.2% | -5.1% |
| December 31, 2023 | $88.46M | -20.2% | -5.9% |
- ATOSSA THERAPEUTICS, INC. showed a decrease of -41.9% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from ATOSSA THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: